{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:11Z","timestamp":1786119131517,"version":"build-2736575974"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/mbc.0b013e3283254570","type":"journal-article","created":{"date-parts":[[2009,2,23]],"date-time":"2009-02-23T03:22:57Z","timestamp":1235359377000},"page":"89-100","source":"Crossref","is-referenced-by-count":31,"title":["Von Willebrand factor\/factor VIII concentrates in the treatment of von Willebrand disease"],"prefix":"10.1097","volume":"20","author":[{"given":"Javier","family":"Batlle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Lour\u00e9s","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Rodr\u00edguez","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Almudena","family":"P\u00e9rez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2516.2002.00672.x","article-title":"Guidelines for the diagnosis and management of von Willebrand disease in Italy. Italian Association of Hemophilia Center (AICE)","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2516.2002.00622.x","article-title":"Advances in the therapy of von Willebrand disease","volume":"8","author":"Batlle","year":"2002","journal-title":"Haemophilia"},{"key":"R4-1-20210203","first-page":"94","article-title":"Von Willebrand disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood.V30.3.375.375","article-title":"Correction of the hemostatic defects in von Willebrand disease","volume":"30","author":"Perkins","year":"1967","journal-title":"Blood"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2516.2004.00893.x","article-title":"A comparative in vitro evaluation of six von Willebrand factor concentrates","volume":"10","author":"Lethagen","year":"2004","journal-title":"Haemophilia"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1351-8216.2003.00809.x","article-title":"Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII\/VWF concentrates (Humate-P)","volume":"10","author":"Thompson","year":"2004","journal-title":"Haemophilia"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1351-8216.2003.00816.x","article-title":"Successful treatment of urgent bleeding in von Willebrand disease with factor VIII\/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy","volume":"9","author":"Gill","year":"2003","journal-title":"Haemophilia"},{"key":"R11-1-20210203","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease","volume":"88","author":"Franchini","year":"2003","journal-title":"Haematologica"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00001721-199304060-00018","article-title":"Biological effects of a S\/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease","volume":"4","author":"Meriane","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R13-1-20210203","first-page":"212","article-title":"Use of a high-purity factor VIII concentrate (Humate-P) in von Willebrand disease","volume":"56","author":"Berntorp","year":"1989","journal-title":"Vox Sang"},{"key":"R14-1-20210203","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease","volume":"71","author":"Hanna","year":"1994","journal-title":"Thromb Haemost"},{"key":"R15-1-20210203","first-page":"304","article-title":"Haemate-P in children with von Willebrand disease","volume":"24","author":"Kreuz","year":"1994","journal-title":"Haemostasis"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial","volume":"79","author":"Mannucci","year":"1992","journal-title":"Blood"},{"issue":"suppl 3","key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand disease with a VHP VWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease","volume":"4","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1612977","article-title":"Efficacy and safety of the factor VIII\/von Willebrand factor concentrate, Haemate-P\/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease","volume":"87","author":"Lillicrap","year":"2002","journal-title":"Thromb Haemost"},{"key":"R21-1-20210203","first-page":"228","article-title":"In vitro and in vivo characterization of a high-purity, solvent\/detergent treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease","volume":"75","author":"Mazurier","year":"1990","journal-title":"Eur J Haematol"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2141.1990.tb02654.x","article-title":"Clinical and laboratory evaluation of the treatment of von Willebrand disease patients with heat treated factor VIII concentrate (BPL 8Y)","volume":"75","author":"Pasi","year":"1990","journal-title":"Br J Haematol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01836069","article-title":"Pharmacokinetics and hemostatic effect of different factor VIII\/von Willebrand factor concentrates in von Willebrand disease type III","volume":"65","author":"Lethagen","year":"1992","journal-title":"Ann Hematol"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"suppl 4","key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2516.2004.00979.x","article-title":"von Willebrand disease: laboratory aspects of diagnosis and treatment","volume":"10","author":"Favaloro","year":"2004","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x","article-title":"Summary of a workshop on potency and dosage of von Willebrand factor concentrates","volume":"4","author":"Chang","year":"1998","journal-title":"Haemophilia"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1613027","article-title":"A comparative multilaboratory assessment of three factor VIII\/von Willebrand factor concentrates","volume":"87","author":"Favaloro","year":"2002","journal-title":"Thromb Haemost"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-2006-947868","article-title":"Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease","volume":"32","author":"Mazurier","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-2006-949668","article-title":"Comparative analysis and classification of von Willebrand factor\/factor VIII concentrates: impact on treatment of patients with von Willebrand disease","volume":"32","author":"Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.0042-9007.2004.00398.x","article-title":"In vitro study of a triple-secured von Willebrand factor concentrate","volume":"86","author":"Mazurier","year":"2004","journal-title":"Vox Sang"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1423-0410.1987.tb02981.x","article-title":"Assessment of multimeric structure and ristocetin-induced binding to platelets of von Willebrand factor present in cryoprecipitate and different factor VIII concentrates","volume":"52","author":"Lopez-Fernandez","year":"1987","journal-title":"Vox Sang"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","article-title":"Proteolysis of von Willebrand factor in therapeutic plasma concentrates","volume":"83","author":"Mannucci","year":"1994","journal-title":"Blood"},{"issue":"suppl 3","key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x","article-title":"Characterization of factor VIII\/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis","volume":"4","author":"Metzner","year":"1998","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"R34-1-20210203","first-page":"10","article-title":"Therapy of von Willebrand disease and its monitoring [In Spanish]","volume":"89","author":"Batlle","year":"2004","journal-title":"Haematologica (Spanish edition)"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0038-1649564","article-title":"Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease","volume":"70","author":"Morfini","year":"1993","journal-title":"Thromb Haemost"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0038-1657590","article-title":"New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates","volume":"78","author":"Menache","year":"1997","journal-title":"Thromb Haemost"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ajh.2830400105","article-title":"Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII","volume":"40","author":"Lopez-Fernandez","year":"1992","journal-title":"Am J Hematol"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1160\/TH06-09-0495","article-title":"Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multicentre study","volume":"97","author":"Favaloro","year":"2007","journal-title":"Thromb Haemost"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1055\/s-2007-1000367","article-title":"Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease","volume":"33","author":"Favaloro","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00001721-200406000-00006","article-title":"Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII \u2013 von Willebrand factor concentrate (Haemate P)","volume":"15","author":"Michiels","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0037-1613768","article-title":"Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand disease (VWD), and discrimination of VWD subtypes, depends on collagen source","volume":"83","author":"Favaloro","year":"2000","journal-title":"Thromb Haemost"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood.V91.4.1325","article-title":"Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases","volume":"91","author":"Fressinaud","year":"1998","journal-title":"Blood"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0037-1614626","article-title":"Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease","volume":"82","author":"Cattaneo","year":"1999","journal-title":"Thromb Haemost"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1160\/TH07-08-0527","article-title":"PFA-100 monitoring of von Willebrand factor (VWF) responses to DDAVP and FVIII\/VWF concentrate substitution in von Willebrand disease type 1 and 2","volume":"100","author":"van Vliet","year":"2008","journal-title":"Thromb Haemost"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH08-07-0449","article-title":"A better approach to monitoring of therapy in von Willebrand disease?","volume":"100","author":"Favaloro","year":"2008","journal-title":"Thromb Haemost"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0037-1614415","article-title":"Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain","volume":"81","author":"Laub","year":"1999","journal-title":"Thromb Haemost"},{"key":"R48-1-20210203","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N Engl J Med"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0037-1613225","article-title":"Venous thromboembolism in von Willebrand disease","volume":"88","author":"Mannucci","year":"2002","journal-title":"Thromb Haemost"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613227","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040161","article-title":"Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children","volume":"351","author":"Goldenberg","year":"2004","journal-title":"N Engl J Med"},{"key":"R54-1-20210203","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMp048150","article-title":"Factor VIII, D-dimer, and thromboembolism in children","volume":"351","author":"Nowak-Gottl","year":"2004","journal-title":"N Engl J Med"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.2003.04795.x","article-title":"High plasma levels of factor VIII and risk of recurrence of venous thromboembolism","volume":"124","author":"Cristina","year":"2004","journal-title":"Br J Haematol"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MBC.0b013e3283254570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:34:23Z","timestamp":1786037663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-200903000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e3283254570","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}